Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression

Results from a 4-week, double-blind, placebo-controlled trial

Chi Un Pae, David M. Marks, Prakash S. Masand, Kathleen Peindl, Christa Hooper-Wood, Changsu Han, Paolo Mannelli, Patrick Ciccone, Ashwin A. Patkar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenidate extended release (OROS MPH) improved sexual dysfunction associated with antidepressants in patients with treatment-resistant major depression. The primary efficacy measure was the change in Arizona Sexual Experiences Survey (ASEX) from baseline to end of treatment in an intent-to-treat analysis with last observation carried forward approach. There were no significant differences between the 2 groups in terms of changes in ASEX scores over time (F 1,35 = 1.14; P = 0.32), although the numerical decrease in ASEX score was greater in OROS MPH (mean change, -4.5; 20.1% decrease) than in the placebo group (mean change, -0.6; 2.6% decrease). Augmentation with OROS MPH showed no statistically significant benefit in antidepressant-related sexual dysfunction, although addition of OROS MPH to antidepressants did not worsen preexisting sexual dysfunction. Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area.

Original languageEnglish
Pages (from-to)85-88
Number of pages4
JournalClinical Neuropharmacology
Volume32
Issue number2
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Treatment-Resistant Depressive Disorder
Methylphenidate
Antidepressive Agents
Placebos
Therapeutics
Observation
5,10-dihydro-5-methylphenazine
Surveys and Questionnaires

Keywords

  • Augmentation
  • Methylphenidate
  • Sexual dysfunction
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression : Results from a 4-week, double-blind, placebo-controlled trial. / Pae, Chi Un; Marks, David M.; Masand, Prakash S.; Peindl, Kathleen; Hooper-Wood, Christa; Han, Changsu; Mannelli, Paolo; Ciccone, Patrick; Patkar, Ashwin A.

In: Clinical Neuropharmacology, Vol. 32, No. 2, 01.03.2009, p. 85-88.

Research output: Contribution to journalArticle

Pae, Chi Un ; Marks, David M. ; Masand, Prakash S. ; Peindl, Kathleen ; Hooper-Wood, Christa ; Han, Changsu ; Mannelli, Paolo ; Ciccone, Patrick ; Patkar, Ashwin A. / Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression : Results from a 4-week, double-blind, placebo-controlled trial. In: Clinical Neuropharmacology. 2009 ; Vol. 32, No. 2. pp. 85-88.
@article{f329b82e5f124e2c8129eb667c518c76,
title = "Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: Results from a 4-week, double-blind, placebo-controlled trial",
abstract = "There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenidate extended release (OROS MPH) improved sexual dysfunction associated with antidepressants in patients with treatment-resistant major depression. The primary efficacy measure was the change in Arizona Sexual Experiences Survey (ASEX) from baseline to end of treatment in an intent-to-treat analysis with last observation carried forward approach. There were no significant differences between the 2 groups in terms of changes in ASEX scores over time (F 1,35 = 1.14; P = 0.32), although the numerical decrease in ASEX score was greater in OROS MPH (mean change, -4.5; 20.1{\%} decrease) than in the placebo group (mean change, -0.6; 2.6{\%} decrease). Augmentation with OROS MPH showed no statistically significant benefit in antidepressant-related sexual dysfunction, although addition of OROS MPH to antidepressants did not worsen preexisting sexual dysfunction. Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area.",
keywords = "Augmentation, Methylphenidate, Sexual dysfunction, Treatment-resistant depression",
author = "Pae, {Chi Un} and Marks, {David M.} and Masand, {Prakash S.} and Kathleen Peindl and Christa Hooper-Wood and Changsu Han and Paolo Mannelli and Patrick Ciccone and Patkar, {Ashwin A.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/WNF.0b013e31817e559b",
language = "English",
volume = "32",
pages = "85--88",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression

T2 - Results from a 4-week, double-blind, placebo-controlled trial

AU - Pae, Chi Un

AU - Marks, David M.

AU - Masand, Prakash S.

AU - Peindl, Kathleen

AU - Hooper-Wood, Christa

AU - Han, Changsu

AU - Mannelli, Paolo

AU - Ciccone, Patrick

AU - Patkar, Ashwin A.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenidate extended release (OROS MPH) improved sexual dysfunction associated with antidepressants in patients with treatment-resistant major depression. The primary efficacy measure was the change in Arizona Sexual Experiences Survey (ASEX) from baseline to end of treatment in an intent-to-treat analysis with last observation carried forward approach. There were no significant differences between the 2 groups in terms of changes in ASEX scores over time (F 1,35 = 1.14; P = 0.32), although the numerical decrease in ASEX score was greater in OROS MPH (mean change, -4.5; 20.1% decrease) than in the placebo group (mean change, -0.6; 2.6% decrease). Augmentation with OROS MPH showed no statistically significant benefit in antidepressant-related sexual dysfunction, although addition of OROS MPH to antidepressants did not worsen preexisting sexual dysfunction. Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area.

AB - There are limited data to indicate effective treatment strategies for antidepressant-related sexual dysfunction, in particular for patients with treatment-resistant major depression. We subanalyzed our published data whether augmentation with methylphenidate extended release (OROS MPH) improved sexual dysfunction associated with antidepressants in patients with treatment-resistant major depression. The primary efficacy measure was the change in Arizona Sexual Experiences Survey (ASEX) from baseline to end of treatment in an intent-to-treat analysis with last observation carried forward approach. There were no significant differences between the 2 groups in terms of changes in ASEX scores over time (F 1,35 = 1.14; P = 0.32), although the numerical decrease in ASEX score was greater in OROS MPH (mean change, -4.5; 20.1% decrease) than in the placebo group (mean change, -0.6; 2.6% decrease). Augmentation with OROS MPH showed no statistically significant benefit in antidepressant-related sexual dysfunction, although addition of OROS MPH to antidepressants did not worsen preexisting sexual dysfunction. Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area.

KW - Augmentation

KW - Methylphenidate

KW - Sexual dysfunction

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=67749133787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749133787&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e31817e559b

DO - 10.1097/WNF.0b013e31817e559b

M3 - Article

VL - 32

SP - 85

EP - 88

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -